Vergelijking
Liraglutide vs. Mazdutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
204656-20-2
2259884-03-0
Molecuulmassa
3751 g/mol
4790 g/mol
Halfwaardetijd
13 h
132 h
Sequentie
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGsynthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteWerkingsmechanisme
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
4
waarvan bij mensen
4
4
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
0
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Liraglutide and Mazdutide?
- Liraglutide is classified as "Metabool", while Mazdutide is classified as "Metabool". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Liraglutide or Mazdutide?
- The highest available evidence level is "Humane RCT" for Liraglutide and "Humane RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Liraglutide and Mazdutide in Germany and the United States?
- Duitsland: Liraglutide — Op recept, Mazdutide — Alleen onderzoek. Verenigde Staten: Liraglutide — Op recept, Mazdutide — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.